99 results on '"Posner MP"'
Search Results
2. Use of extracorporeal membrane oxygenation for adult respiratory distress syndrome following cadaveric renal transplantation
- Author
-
Posner Mp, Wechsler As, Greenfield Dt, and Lofland Gk
- Subjects
Adult ,Male ,Transplantation ,medicine.medical_specialty ,Kidney ,Respiratory Distress Syndrome ,Respiratory distress ,business.industry ,medicine.medical_treatment ,Respiratory disease ,medicine.disease ,Kidney Transplantation ,medicine.anatomical_structure ,Extracorporeal Membrane Oxygenation ,Respiratory failure ,medicine ,Extracorporeal membrane oxygenation ,Cadaver ,Humans ,Cadaveric spasm ,Intensive care medicine ,Complication ,business ,Muromonab-CD3 - Published
- 1993
3. Intragraft cytokine expressionf in tolerant rat renal allografts with rapamycin and cyclosporin immunosuppression
- Author
-
Saggi, Bh, primary, Fisher, Ra, additional, Naar, Jd, additional, Bu, D, additional, Obias, V, additional, Tawes, Jw, additional, Wakely Jr, Paul E, additional, and Posner, Mp, additional
- Published
- 1999
- Full Text
- View/download PDF
4. Characterizing the risk of human leukocyte antigen-incompatible living donor kidney transplantation in older recipients.
- Author
-
Long JJ, Motter JD, Jackson KR, Chen J, Orandi BJ, Montgomery RA, Stegall MD, Jordan SC, Benedetti E, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Verbesey JE, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Wellen JR, Bozorgzadeh A, Gaber AO, Heher EC, Weng FL, Djamali A, Helderman JH, Concepcion BP, Brayman KL, Oberholzer J, Kozlowski T, Covarrubias K, Massie AB, McAdams-DeMarco MA, Segev DL, and Garonzik-Wang JM
- Subjects
- Humans, Aged, Middle Aged, Adolescent, Young Adult, Adult, Living Donors, Graft Survival, Graft Rejection etiology, HLA Antigens, Risk Factors, Kidney Transplantation adverse effects
- Abstract
Older compatible living donor kidney transplant (CLDKT) recipients have higher mortality and death-censored graft failure (DCGF) compared to younger recipients. These risks may be amplified in older incompatible living donor kidney transplant (ILDKT) recipients who undergo desensitization and intense immunosuppression. In a 25-center cohort of ILDKT recipients transplanted between September 24, 1997, and December 15, 2016, we compared mortality, DCGF, delayed graft function (DGF), acute rejection (AR), and length of stay (LOS) between 234 older (age ≥60 years) and 1172 younger (age 18-59 years) recipients. To investigate whether the impact of age was different for ILDKT recipients compared to 17 542 CLDKT recipients, we used an interaction term to determine whether the relationship between posttransplant outcomes and transplant type (ILDKT vs CLDKT) was modified by age. Overall, older recipients had higher mortality (hazard ratio:
1.63 2.072.65 , P < .001), lower DCGF (hazard ratio:0.36 0.530.77 , P = .001), and AR (odds ratio:0.39 0.540.74 , P < .001), and similar DGF (odds ratio:0.46 1.032.33 , P = .9) and LOS (incidence rate ratio:0.88 0.981.10 , P = 0.8) compared to younger recipients. The impact of age on mortality (interaction P = .052), DCGF (interaction P = .7), AR interaction P = .2), DGF (interaction P = .9), and LOS (interaction P = .5) were similar in ILDKT and CLDKT recipients. Age alone should not preclude eligibility for ILDKT., (Copyright © 2023 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
5. Delayed graft function and acute rejection following HLA-incompatible living donor kidney transplantation.
- Author
-
Motter JD, Jackson KR, Long JJ, Waldram MM, Orandi BJ, Montgomery RA, Stegall MD, Jordan SC, Benedetti E, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Verbesey JE, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Wellen JR, Bozorgzadeh A, Gaber AO, Heher EC, Weng FL, Djamali A, Helderman JH, Concepcion BP, Brayman KL, Oberholzer J, Kozlowski T, Covarrubias K, Massie AB, Segev DL, and Garonzik-Wang JM
- Subjects
- Delayed Graft Function etiology, Graft Rejection etiology, Graft Survival, Humans, Living Donors, Retrospective Studies, Risk Factors, Kidney Transplantation adverse effects
- Abstract
Incompatible living donor kidney transplant recipients (ILDKTr) have pre-existing donor-specific antibody (DSA) that, despite desensitization, may persist or reappear with resulting consequences, including delayed graft function (DGF) and acute rejection (AR). To quantify the risk of DGF and AR in ILDKT and downstream effects, we compared 1406 ILDKTr to 17 542 compatible LDKT recipients (CLDKTr) using a 25-center cohort with novel SRTR linkage. We characterized DSA strength as positive Luminex, negative flow crossmatch (PLNF); positive flow, negative cytotoxic crossmatch (PFNC); or positive cytotoxic crossmatch (PCC). DGF occurred in 3.1% of CLDKT, 3.5% of PLNF, 5.7% of PFNC, and 7.6% of PCC recipients, which translated to higher DGF for PCC recipients (aOR =
1.03 1.682.72 ). However, the impact of DGF on mortality and DCGF risk was no higher for ILDKT than CLDKT (p interaction > .1). AR developed in 8.4% of CLDKT, 18.2% of PLNF, 21.3% of PFNC, and 21.7% of PCC recipients, which translated to higher AR (aOR PLNF =1.45 2.093.02 ; PFNC =1.67 2.403.46 ; PCC =1.48 2.243.37 ). Although the impact of AR on mortality was no higher for ILDKT than CLDKT (p interaction = .1), its impact on DCGF risk was less consequential for ILDKT (aHR =1.34 1.621.95 ) than CLDKT (aHR =1.96 2.292.67 ) (p interaction = .004). Providers should consider these risks during preoperative counseling, and strategies to mitigate them should be considered., (© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.)- Published
- 2021
- Full Text
- View/download PDF
6. Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes.
- Author
-
Jackson KR, Long J, Motter J, Bowring MG, Chen J, Waldram MM, Orandi BJ, Montgomery RA, Stegall MD, Jordan SC, Benedetti E, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Verbesey JE, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Wellen J, Bozorgzadeh A, Gaber AO, Heher E, Weng FL, Djamali A, Helderman JH, Concepcion BP, Brayman KL, Oberholzer J, Kozlowski T, Covarrubias K, Desai N, Massie AB, Segev DL, and Garonzik-Wang J
- Subjects
- Adult, Female, Graft Rejection blood, Graft Rejection immunology, Graft Rejection mortality, Humans, Immunosuppressive Agents adverse effects, Male, Middle Aged, Quality Indicators, Health Care, Registries, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, United States, Graft Rejection prevention & control, Graft Survival drug effects, HLA Antigens immunology, Healthcare Disparities, Histocompatibility, Immunosuppressive Agents therapeutic use, Isoantibodies blood, Kidney Transplantation adverse effects, Kidney Transplantation mortality, Living Donors, Practice Patterns, Physicians'
- Abstract
Background: Desensitization protocols for HLA-incompatible living donor kidney transplantation (ILDKT) vary across centers. The impact of these, as well as other practice variations, on ILDKT outcomes remains unknown., Methods: We sought to quantify center-level variation in mortality and graft loss following ILDKT using a 25-center cohort of 1358 ILDKT recipients with linkage to Scientific Registry of Transplant Recipients for accurate outcome ascertainment. We used multilevel Cox regression with shared frailty to determine the variation in post-ILDKT outcomes attributable to between-center differences and to identify any center-level characteristics associated with improved post-ILDKT outcomes., Results: After adjusting for patient-level characteristics, only 6 centers (24%) had lower mortality and 1 (4%) had higher mortality than average. Similarly, only 5 centers (20%) had higher graft loss and 2 had lower graft loss than average. Only 4.7% of the differences in mortality (P < 0.01) and 4.4% of the differences in graft loss (P < 0.01) were attributable to between-center variation. These translated to a median hazard ratio of 1.36 for mortality and 1.34 of graft loss for similar candidates at different centers. Post-ILDKT outcomes were not associated with the following center-level characteristics: ILDKT volume and transplanting a higher proportion of highly sensitized, prior transplant, preemptive, or minority candidates., Conclusions: Unlike most aspects of transplantation in which center-level variation and volume impact outcomes, we did not find substantial evidence for this in ILDKT. Our findings support the continued practice of ILDKT across these diverse centers., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
7. Hospital readmissions following HLA-incompatible live donor kidney transplantation: A multi-center study.
- Author
-
Orandi BJ, Luo X, King EA, Garonzik-Wang JM, Bae S, Montgomery RA, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Nelson PW, Wellen J, Bozorgzadeh A, Osama Gaber A, and Segev DL
- Subjects
- Adult, Case-Control Studies, Female, Follow-Up Studies, Glomerular Filtration Rate, Graft Survival, Hospitalization statistics & numerical data, Humans, Isoantibodies blood, Isoantibodies immunology, Kidney Function Tests, Male, Middle Aged, Prognosis, Risk Factors, Blood Group Incompatibility immunology, HLA Antigens immunology, Kidney Failure, Chronic surgery, Kidney Transplantation methods, Living Donors supply & distribution, Patient Readmission statistics & numerical data, Postoperative Complications
- Abstract
Thirty percent of kidney transplant recipients are readmitted in the first month posttransplantation. Those with donor-specific antibody requiring desensitization and incompatible live donor kidney transplantation (ILDKT) constitute a unique subpopulation that might be at higher readmission risk. Drawing on a 22-center cohort, 379 ILDKTs with Medicare primary insurance were matched to compatible transplant-matched controls and to waitlist-only matched controls on panel reactive antibody, age, blood group, renal replacement time, prior kidney transplantation, race, gender, diabetes, and transplant date/waitlisting date. Readmission risk was determined using multilevel, mixed-effects Poisson regression. In the first month, ILDKTs had a 1.28-fold higher readmission risk than compatible controls (95% confidence interval [CI] 1.13-1.46; P < .001). Risk peaked at 6-12 months (relative risk [RR] 1.67, 95% CI 1.49-1.87; P < .001), attenuating by 24-36 months (RR 1.24, 95% CI 1.10-1.40; P < .001). ILDKTs had a 5.86-fold higher readmission risk (95% CI 4.96-6.92; P < .001) in the first month compared to waitlist-only controls. At 12-24 (RR 0.85, 95% CI 0.77-0.95; P = .002) and 24-36 months (RR 0.74, 95% CI 0.66-0.84; P < .001), ILDKTs had a lower risk than waitlist-only controls. These findings of ILDKTs having a higher readmission risk than compatible controls, but a lower readmission risk after the first year than waitlist-only controls should be considered in regulatory/payment schemas and planning clinical care., (© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2018
- Full Text
- View/download PDF
8. The Incremental Cost of Incompatible Living Donor Kidney Transplantation: A National Cohort Analysis.
- Author
-
Axelrod D, Lentine KL, Schnitzler MA, Luo X, Xiao H, Orandi BJ, Massie A, Garonzik-Wang J, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Nelson PW, Wellen J, Bozorgzadeh A, Osama Gaber A, Montgomery RA, and Segev DL
- Subjects
- Case-Control Studies, Female, Follow-Up Studies, Glomerular Filtration Rate, Graft Rejection epidemiology, Graft Survival, Humans, Kidney Function Tests, Male, Middle Aged, Prognosis, Quality of Life, Retrospective Studies, Risk Factors, Blood Group Incompatibility economics, Graft Rejection economics, Histocompatibility Testing economics, Kidney Failure, Chronic surgery, Kidney Transplantation economics, Living Donors, Postoperative Complications economics
- Abstract
Incompatible living donor kidney transplantation (ILDKT) has been established as an effective option for end-stage renal disease patients with willing but HLA-incompatible living donors, reducing mortality and improving quality of life. Depending on antibody titer, ILDKT can require highly resource-intensive procedures, including intravenous immunoglobulin, plasma exchange, and/or cell-depleting antibody treatment, as well as protocol biopsies and donor-specific antibody testing. This study sought to compare the cost and Medicare reimbursement, exclusive of organ acquisition payment, for ILDKT (n = 926) with varying antibody titers to matched compatible transplants (n = 2762) performed between 2002 and 2011. Data were assembled from a national cohort study of ILDKT and a unique data set linking hospital cost accounting data and Medicare claims. ILDKT was more expensive than matched compatible transplantation, ranging from 20% higher adjusted costs for positive on Luminex assay but negative flow cytometric crossmatch, 26% higher for positive flow cytometric crossmatch but negative cytotoxic crossmatch, and 39% higher for positive cytotoxic crossmatch (p < 0.0001 for all). ILDKT was associated with longer median length of stay (12.9 vs. 7.8 days), higher Medicare payments ($91 330 vs. $63 782 p < 0.0001), and greater outlier payments. In conclusion, ILDKT increases the cost of and payments for kidney transplantation., (© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2017
- Full Text
- View/download PDF
9. Outcomes of kidney transplants and risk of infection transmission from increased infectious risk donors.
- Author
-
Limkemann AJ, Wolfe L, Sharma A, King AL, Behnke M, Shah MJ, Posner MP, Cotterell AH, Bhati CS, Gupta A, Kumar D, and Gupta G
- Subjects
- Adult, Disease Transmission, Infectious prevention & control, Female, Graft Survival, Humans, Incidence, Infections epidemiology, Male, Retrospective Studies, United States epidemiology, Disease Transmission, Infectious statistics & numerical data, Infections transmission, Kidney Transplantation adverse effects, Registries, Tissue Donors, Tissue and Organ Procurement methods
- Abstract
Concern over transmission of viral infections has been reported to result in higher discard rates of high infectious risk kidneys (HIR) although data on actual viral transmission rates are lacking. At our center, we performed 89 HIR and 533 non-HIR kidney transplants (KTs) between 2004 and 2011. Follow-up screening labs in recipients of HIR kidneys tested for human immunodeficiency virus, hepatitis C virus, and hepatitis B virus did not reveal any cases of viral transmission over median follow-up of 4.3 years. Patient and graft outcomes were similar at 5 years between HIR and non-HIR KTs. An updated analysis of the Organ Procurement and Transplant Network (OPTN) registry of deceased-donor kidney transplants between 2008 and 2012 included 57 526 transplants was performed. Retrospective calculation of KDRI (kidney donor risk index) differed (P<.001) between all groups with median KDRI of 0.99 for HIR kidneys, 1.07 for non-HIR standard criteria donor kidneys, and 1.81 for non-HIR expanded criteria donor (ECD) kidneys. This was reflected in the significantly improved 5-year graft survival for HIR KTs when compared with non-HIR ECD KTs (84% vs 78%; P<.001). Our data can guide counseling of KT candidates about the safety and benefits of HIR kidneys., (© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
10. Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors.
- Author
-
Orandi BJ, Luo X, Massie AB, Garonzik-Wang JM, Lonze BE, Ahmed R, Van Arendonk KJ, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Nelson PW, Wellen J, Bozorgzadeh A, Gaber AO, Montgomery RA, and Segev DL
- Subjects
- Graft Survival, HLA Antigens, Histocompatibility Testing, Humans, Survival Analysis, Tissue and Organ Procurement, Waiting Lists, Histocompatibility, Kidney Transplantation mortality, Living Donors
- Abstract
Background: A report from a high-volume single center indicated a survival benefit of receiving a kidney transplant from an HLA-incompatible live donor as compared with remaining on the waiting list, whether or not a kidney from a deceased donor was received. The generalizability of that finding is unclear., Methods: In a 22-center study, we estimated the survival benefit for 1025 recipients of kidney transplants from HLA-incompatible live donors who were matched with controls who remained on the waiting list or received a transplant from a deceased donor (waiting-list-or-transplant control group) and controls who remained on the waiting list but did not receive a transplant (waiting-list-only control group). We analyzed the data with and without patients from the highest-volume center in the study., Results: Recipients of kidney transplants from incompatible live donors had a higher survival rate than either control group at 1 year (95.0%, vs. 94.0% for the waiting-list-or-transplant control group and 89.6% for the waiting-list-only control group), 3 years (91.7% vs. 83.6% and 72.7%, respectively), 5 years (86.0% vs. 74.4% and 59.2%), and 8 years (76.5% vs. 62.9% and 43.9%) (P<0.001 for all comparisons with the two control groups). The survival benefit was significant at 8 years across all levels of donor-specific antibody: 89.2% for recipients of kidney transplants from incompatible live donors who had a positive Luminex assay for anti-HLA antibody but a negative flow-cytometric cross-match versus 65.0% for the waiting-list-or-transplant control group and 47.1% for the waiting-list-only control group; 76.3% for recipients with a positive flow-cytometric cross-match but a negative cytotoxic cross-match versus 63.3% and 43.0% in the two control groups, respectively; and 71.0% for recipients with a positive cytotoxic cross-match versus 61.5% and 43.7%, respectively. The findings did not change when patients from the highest-volume center were excluded., Conclusions: This multicenter study validated single-center evidence that patients who received kidney transplants from HLA-incompatible live donors had a substantial survival benefit as compared with patients who did not undergo transplantation and those who waited for transplants from deceased donors. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases.).
- Published
- 2016
- Full Text
- View/download PDF
11. Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction.
- Author
-
Gupta G, Regmi A, Kumar D, Posner S, Posner MP, Sharma A, Cotterell A, Bhati CS, Kimball P, Massey HD, and King AL
- Subjects
- Adult, Aged, Allografts drug effects, Allografts physiopathology, Female, Follow-Up Studies, Humans, Immunosuppressive Agents adverse effects, Male, Middle Aged, Retrospective Studies, Tacrolimus therapeutic use, Transplantation, Homologous, Treatment Outcome, Abatacept therapeutic use, Graft Rejection prevention & control, Immunosuppressive Agents therapeutic use, Kidney Transplantation, Postoperative Complications chemically induced, Renal Insufficiency chemically induced, Tacrolimus adverse effects
- Abstract
There is no literature on the use of belatacept for sensitized patients or regrafts in kidney transplantation. We present our initial experience in high immunologic risk kidney transplant recipients who were converted from tacrolimus to belatacept for presumed acute calcineurin inhibitor (CNI) toxicity and/or interstitial fibrosis/tubular atrophy. Six (mean age = 40 years) patients were switched from tacrolimus to belatacept at a median of 4 months posttransplant. Renal function improved significantly from a peak mean estimated glomerular filtration rate (eGFR) of 23.8 ± 12.9 mL/min/1.73 m(2) prior to the switch to an eGFR of 42 ± 12.5 mL/min/1.73 m(2) (p = 0.03) at a mean follow-up of 16.5 months postconversion. No new rejection episodes were diagnosed despite a prior history of rejection in 2/6 (33%) patients. Surveillance biopsies performed in 5/6 patients did not show subclinical rejection. No development of donor-specific antibodies (DSA) was noted. In this preliminary investigation, we report improved kidney function without a concurrent increase in risk of rejection and DSA in six sensitized patients converted from tacrolimus to belatacept. Improvement in renal function was noted even in patients with chronic allograft fibrosis without evidence of acute CNI toxicity. Further studies with protocol biopsies are needed to ensure safety and wider applicability of this approach., (© Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2015
- Full Text
- View/download PDF
12. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.
- Author
-
Ramanathan R, Sharma A, Lee DD, Behnke M, Bornstein K, Stravitz RT, Sydnor M, Fulcher A, Cotterell A, Posner MP, and Fisher RA
- Subjects
- Aged, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular pathology, Chemotherapy, Adjuvant, Disease-Free Survival, Female, Humans, Liver Neoplasms mortality, Liver Neoplasms pathology, Male, Middle Aged, Neoplasm Recurrence, Local, Niacinamide therapeutic use, Prospective Studies, Radiotherapy, Adjuvant, Risk Factors, Sorafenib, Time Factors, Treatment Outcome, Carcinoma, Hepatocellular therapy, Catheter Ablation adverse effects, Catheter Ablation mortality, Chemoembolization, Therapeutic adverse effects, Chemoembolization, Therapeutic mortality, Hepatectomy adverse effects, Hepatectomy mortality, Liver Neoplasms therapy, Liver Transplantation adverse effects, Liver Transplantation mortality, Niacinamide analogs & derivatives, Phenylurea Compounds therapeutic use, Protein Kinase Inhibitors therapeutic use, Radiopharmaceuticals therapeutic use, Yttrium Radioisotopes therapeutic use
- Abstract
Background: Hepatocellular carcinoma is a major cause of death among patients with cirrhosis. A standardized approach of multimodality therapy with intent-to-treat by transplantation for all patients with hepatocellular carcinoma was instituted at our transplant center in 1997. Data were prospectively collected to evaluate the impact of multimodality therapy on posttransplant patient survival, tumor recurrence, and patient survival without transplantation., Methods: All patients with hepatocellular carcinoma were eligible for multimodality therapy. Multimodality therapy consisted of hepatic resection, radiofrequency ablation, transarterial chemoembolization, transarterial chemoinfusion, yttrium-90 microsphere radioembolization, and sorafenib., Results: Approximately 715 patients underwent multimodality therapy; 231 patients were included in the intent-to-treat with transplantation arm, and 484 patients were treated with multimodality therapy or palliative therapy because of contraindications for transplantation. A 60.2% transplantation rate was achieved in the intent-to-treat with transplantation arm. Posttransplant survivals at 1 and 5 years were 97.1% and 72.5%, respectively. Tumor recurrence rates at 1, 3, and 5 years were 2.4%, 6.2%, and 11.6%, respectively. Patients with contraindications to transplant had increased 1- and 5-year survival from diagnosis with multimodality therapy compared with those not treated (73.1% and 46.5% versus 15.5% and 4.4%, P<0.0001)., Conclusions: Using multimodality therapy before liver transplantation for hepatocellular carcinoma achieved low recurrence rates and posttransplant survival equivalent to patients with primary liver disease without hepatocellular carcinoma. Multimodality therapy may help identify patients with less active tumor biology and result in improved disease-free survival and organ utilization.
- Published
- 2014
- Full Text
- View/download PDF
13. Quantifying the risk of incompatible kidney transplantation: a multicenter study.
- Author
-
Orandi BJ, Garonzik-Wang JM, Massie AB, Zachary AA, Montgomery JR, Van Arendonk KJ, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Nelson PW, Wellen J, Bozorgzadeh A, Gaber AO, Montgomery RA, and Segev DL
- Subjects
- Adult, Blood Group Incompatibility diagnosis, Blood Group Incompatibility immunology, Female, Follow-Up Studies, Graft Survival, Humans, Incidence, Kidney Failure, Chronic mortality, Kidney Failure, Chronic surgery, Male, Middle Aged, Postoperative Complications mortality, Practice Patterns, Physicians' statistics & numerical data, Prognosis, Risk Factors, Survival Rate, Antibodies immunology, Blood Group Incompatibility epidemiology, Graft Rejection etiology, HLA Antigens immunology, Kidney Transplantation legislation & jurisprudence, Kidney Transplantation statistics & numerical data, Living Donors supply & distribution
- Abstract
Incompatible live donor kidney transplantation (ILDKT) offers a survival advantage over dialysis to patients with anti-HLA donor-specific antibody (DSA). Program-specific reports (PSRs) fail to account for ILDKT, placing this practice at regulatory risk. We collected DSA data, categorized as positive Luminex, negative flow crossmatch (PLNF) (n = 185), positive flow, negative cytotoxic crossmatch (PFNC) (n = 536) or positive cytotoxic crossmatch (PCC) (n = 304), from 22 centers. We tested associations between DSA, graft loss and mortality after adjusting for PSR model factors, using 9669 compatible patients as a comparison. PLNF patients had similar graft loss; however, PFNC (adjusted hazard ratio [aHR] = 1.64, 95% confidence interval [CI]: 1.15-2.23, p = 0.007) and PCC (aHR = 5.01, 95% CI: 3.71-6.77, p < 0.001) were associated with increased graft loss in the first year. PLNF patients had similar mortality; however, PFNC (aHR = 2.04; 95% CI: 1.28-3.26; p = 0.003) and PCC (aHR = 4.59; 95% CI: 2.98-7.07; p < 0.001) were associated with increased mortality. We simulated Centers for Medicare & Medicaid Services flagging to examine ILDKT's effect on the risk of being flagged. Compared to equal-quality centers performing no ILDKT, centers performing 5%, 10% or 20% PFNC had a 1.19-, 1.33- and 1.73-fold higher odds of being flagged. Centers performing 5%, 10% or 20% PCC had a 2.22-, 4.09- and 10.72-fold higher odds. Failure to account for ILDKT's increased risk places centers providing this life-saving treatment in jeopardy of regulatory intervention., (© Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2014
- Full Text
- View/download PDF
14. Commercial surrogacy: how provisions of monetary remuneration and powers of international law can prevent exploitation of gestational surrogates.
- Author
-
Ramskold LA and Posner MP
- Subjects
- Asia, Southeastern, Coercion, Female, Humans, Income, Internationality legislation & jurisprudence, Medical Tourism ethics, Medical Tourism legislation & jurisprudence, Personal Autonomy, Reproductive Techniques, Assisted legislation & jurisprudence, Self-Help Groups, Social Justice, United Kingdom, United States, Commerce ethics, Commerce legislation & jurisprudence, International Cooperation legislation & jurisprudence, Legislation, Medical trends, Poverty, Pregnancy psychology, Remuneration, Surrogate Mothers legislation & jurisprudence, Vulnerable Populations
- Abstract
Increasing globalisation and advances in artificial reproductive techniques have opened up a whole new range of possibilities for infertile couples across the globe. Inter-country gestational surrogacy with monetary remuneration is one of the products of medical tourism meeting in vitro fertilisation embryo transfer. Filled with potential, it has also been a hot topic of discussion in legal and bioethics spheres. Fears of exploitation and breach of autonomy have sprung from the current situation, where there is no international regulation of surrogacy agreements--only a web of conflicting national laws that generates loopholes and removes safeguards for both the surrogate and commissioning couple. This article argues the need for evidence-based international laws and regulations as the only way to resolve both the ethical and legal issues around commercial surrogacy. In addition, a Hague Convention on inter-country surrogacy agreements is proposed to resolve the muddled state of affairs and enable commercial surrogacy to demonstrate its full potential.
- Published
- 2013
- Full Text
- View/download PDF
15. Graft-versus-host disease after solid organ transplantation: a single center experience and review of literature.
- Author
-
Sharma A, Armstrong AE, Posner MP, Kimball PM, Cotterell AH, King AL, Fisher RA, and Godder K
- Subjects
- Adolescent, Adult, Fatal Outcome, Graft vs Host Disease etiology, Graft vs Host Reaction, Humans, Infant, Newborn, Male, Graft vs Host Disease diagnosis, Kidney Transplantation immunology, Liver Transplantation immunology, Pancreas Transplantation immunology, Postoperative Complications diagnosis
- Abstract
Background: Graft-versus-host disease (GVHD) is an uncommon cause of morbidity and mortality after solid organ transplantation that is most likely under-diagnosed. We describe our single center experience with three cases of GVHD diagnosed over a period of 15 years in a total of 2,271 solid organ transplant recipients., Case Reports: We describe three case reports: (1) a 3-week old neonate who developed GVHD 16 months after living-related liver transplant, (2) a 14-year old adolescent who developed GVHD 4 months following an unrelated cadaveric pancreas transplant and; (3) a 27-year old male who developed GVHD 18 days after simultaneous kidney-pancreas transplant from an unrelated donor. GVHD was confirmed through skin biopsies, engraftment profile from bone marrow biopsy and variable number tandem repeat analysis. Treatment strategies included use of corticosteroids and sirolimus monotherapy, corticosteroids and mesenchymal stromal cell therapy and reduction of immunosuppression. We observed that African-American race, sexual and HLA mismatching and cytomegalovirus infection may be high risk factors for development of GVHD following solid organ transplant., Conclusions: GVHD continues to be a rare but fatal complication following solid organ transplantation that demands a high index of clinical suspicion for diagnosis and management. Future approaches may focus on early recognition of risk factors and improving treatment protocols using a combination of mesenchymal stromal cell transplantation with pharmacotherapy.
- Published
- 2012
- Full Text
- View/download PDF
16. Identification of biomarkers to assess organ quality and predict posttransplantation outcomes.
- Author
-
Scian MJ, Maluf DG, Archer KJ, Turner SD, Suh JL, David KG, King AL, Posner MP, Brayman KL, and Mas VR
- Subjects
- Biomarkers, Glomerular Filtration Rate, Humans, Oligonucleotide Array Sequence Analysis, Proportional Hazards Models, Signal Transduction, Transplantation, Homologous, Kidney Transplantation, Tissue Donors, Transcriptome
- Abstract
Unlabelled: The increased disparity between organ supply and need has led to the use of extended criteria donors and donation after cardiac death donors with other comorbidities., Methods: We have examined the preimplantation transcriptome of 112 kidney transplant recipient samples from 100 deceased-donor kidneys by microarray profiling. Subject groups were segregated based on estimated glomerular filtration rate (eGFR) at 1 month after transplantation: the GFR-high group (n=74) included patients with eGFR 45 mL/min per 1.73 m(2), whereas the GFR-low group (n=35) included patients with eGFR 45 mL/min or less per 1.73 m(2)., Results: Gene expression profiling identified higher expression of 160 probe sets (140 genes) in the GFR-low group, whereas expression of 37 probe sets (33 genes) was higher in the GFR-high group (P<0.01, false discovery rate <0.2). Four genes (CCL5, CXCR4, ITGB2, and EGF) were selected based on fold change and P value and further validated using an independent set of samples. A random forest analysis identified three of these genes (CCL5, CXCR4, and ITGB2) as important predictors of graft function after transplantation., Conclusions: Inclusion of pretransplantation molecular gene expression profiles in donor quality assessment systems may provide the necessary information for better donor organ selection and function prediction. These biomarkers would further allow a more objective and complete assessment of procured renal allografts at pretransplantation time.
- Published
- 2012
- Full Text
- View/download PDF
17. Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation.
- Author
-
Stravitz RT, Shiffman ML, Kimmel M, Puri P, Luketic VA, Sterling RK, Sanyal AJ, Cotterell AH, Posner MP, and Fisher RA
- Subjects
- Adenine economics, Adenine therapeutic use, Adult, Antiviral Agents economics, Deoxycytidine economics, Deoxycytidine therapeutic use, Emtricitabine, Female, Hepatitis B economics, Humans, Immunoglobulins economics, Male, Middle Aged, Organophosphonates economics, Secondary Prevention, Tenofovir, Adenine analogs & derivatives, Antiviral Agents therapeutic use, Deoxycytidine analogs & derivatives, Hepatitis B prevention & control, Hepatitis B surgery, Immunoglobulins therapeutic use, Liver Transplantation, Organophosphonates therapeutic use
- Abstract
Background: Hepatitis B immune globulin (HBIg) with or without nucleos(t)ide analogue (NA) inhibitors has been shown to prevent recurrence of hepatitis B virus (HBV) following orthotopic liver transplantation (OLT). However, the use of HBIg has many disadvantages., Aims: The present study was performed to determine if converting patients from HBIg ± NA to combination NA therapy could prevent recurrence of HBV., Methods: Twenty-one recipients without evidence of HBV recurrence on HBIg ± NA for ≥ 6 months were enrolled. Patients received their last injection of HBIg at the time they initiated tenofovir disoproxil fumarate/emtricitabine (TDF/FTC; Truvada(®) ) and were followed up for 31.1 ± 9.0 [range 15-47] months., Results: After 1 year, 3 patients (14%) had detectable HBsAg, one of whom was non-compliant. Two of 3 with recurrence cleared HBsAg by last follow-up on TDF/FTC; the non-compliant patient became HBV DNA-undetectable with re-institution of TDF/FTC. TDF/FTC saved $12,469/year over our standard-of-care, monthly intramuscular HBIg/lamivudine. There was no evidence of a general adverse effect of TDF/FTC on renal function. However, 3 patients developed reversible acute renal failure; on renal biopsy, 1 had possible TDF/FTC-induced acute tubular necrosis., Conclusions: Substitution of TDF/FTC for HBIg prevented recurrence of HBV DNA in 100% (20/20) of patients who were compliant with the medication and led to substantial cost savings over HBIg-containing regimens., (© 2012 John Wiley & Sons A/S.)
- Published
- 2012
- Full Text
- View/download PDF
18. Reduced expression of inflammatory genes in deceased donor kidneys undergoing pulsatile pump preservation.
- Author
-
Mas VR, Archer KJ, Dumur CI, Scian MJ, Suh JL, King AL, Wardius ME, Straub JA, Posner MP, Brayman K, and Maluf DG
- Subjects
- Adult, Aged, Biopsy, Cadaver, Delayed Graft Function epidemiology, Female, Gene Expression Regulation, Humans, Inflammation genetics, Inflammation immunology, Kidney immunology, Male, Middle Aged, Young Adult, Gene Expression Profiling, Kidney metabolism, Kidney Transplantation immunology, Kidney Transplantation methods, Organ Preservation methods
- Abstract
Background: The use of expanded criteria donor kidneys (ECD) had been associated with worse outcomes. Whole gene expression of pre-implantation allograft biopsies from deceased donor kidneys (DDKs) was evaluated to compare the effect of pulsatile pump preservation (PPP) vs. cold storage preservation (CSP) on standard and ECD kidneys., Methodology/principal Findings: 99 pre-implantation DDK biopsies were studied using gene expression with GeneChips. Kidneys transplant recipients were followed post transplantation for 35.8 months (range = 24-62). The PPP group included 60 biopsies (cold ischemia time (CIT) = 1,367+/-509 minutes) and the CSP group included 39 biopsies (CIT = 1,022+/-485 minutes) (P<0.001). Donor age (42.0±14.6 vs. 34.1±14.2 years, P = 0.009) and the percentage of ECD kidneys (PPP = 35% vs. CSP = 12.8%, P = 0.012) were significantly different between groups. A two-sample t-test was performed, and probe sets having a P<0.001 were considered significant. Probe set level linear models were fit using cold ischemia time and CSP/PPP as independent variables to determine significant probe sets (P<0.001) between groups after adjusting for cold ischemia time. Thus, 43 significant genes were identified (P<0.001). Over-expression of genes associated with inflammation (CD86, CD209, CLEC4, EGFR2, TFF3, among others) was observed in the CSP group. Cell-to-cell signaling and interaction, and antigen presentation were the most important pathways with genes significantly over-expressed in CSP kidneys. When the analysis was restricted to ECD kidneys, genes involved in inflammation were also differentially up-regulated in ECD kidneys undergoing CSP. However, graft survival at the end of the study was similar between groups (P = 0.2). Moreover, the incidence of delayed graft function was not significant between groups., Conclusions/significance: Inflammation was the most important up-regulated pattern associated with pre-implantation biopsies undergoing CSP even when the PPP group has a larger number of ECD kidneys. No significant difference was observed in delayed graft function incidence and graft function post-transplantation. These findings support the use of PPP in ECD donor kidneys.
- Published
- 2012
- Full Text
- View/download PDF
19. En bloc kidney transplantation from pediatric donors: comparable outcomes with living donor kidney transplantation.
- Author
-
Sharma A, Fisher RA, Cotterell AH, King AL, Maluf DG, and Posner MP
- Subjects
- Adult, Body Weight, Cadaver, Child, Preschool, Female, Graft Survival, Humans, Infant, Kidney Transplantation adverse effects, Male, Middle Aged, Patient Selection, Retrospective Studies, Time Factors, Treatment Outcome, Kidney Transplantation methods, Living Donors, Tissue Donors
- Abstract
Background: En bloc kidneys from pediatric donors have been considered suboptimal for transplantation to adult recipients and their outcomes have rarely been compared with living donor kidney transplantation (LDKT). Traditionally, there has been hesitancy in transplanting en bloc kidneys from donors weighing less than 10 kg due to high risk of technical complications., Methods: Retrospective chart reviews were performed to compare outcomes after pediatric en bloc (n=20, mean donor weight 11.4 kg), standard criteria deceased (n=249), and living donor (n=215) kidney transplantation in adult recipients at our center. The outcomes after en bloc transplantation from young donors weighing less than or equal to 10 kg were compared with those from 11 to 15 kg donors., Results: The 5-year graft survival after en bloc, standard deceased, and LDKT were 92%, 70%, and 88%, respectively (P=ns). There were no vascular complications, and urine leak was seen in 1 of 20 en bloc transplants. The 1-year serum creatinine of 1.1±0.2 mg/dL in recipients from less than or equal to 10 kg donors was comparable with 0.9±0.5 mg/dL in 11 to 15 kg group (P=ns)., Conclusions: Excellent long-term outcome after pediatric en bloc kidney transplantation from donors weighing less than or equal to 15 kg are comparable with those after LDKT. By using meticulous surgical technique and judicious recipient selection criteria, technical graft losses can be minimized when using en bloc pediatric kidneys from donors weighing less than or equal to 10 kg. Use of pediatric en bloc kidneys should be encouraged continuously to address the problem of organ shortage.
- Published
- 2011
- Full Text
- View/download PDF
20. Gene expression changes are associated with loss of kidney graft function and interstitial fibrosis and tubular atrophy: diagnosis versus prediction.
- Author
-
Scian MJ, Maluf DG, Archer KJ, Suh JL, Massey D, Fassnacht RC, Whitehill B, Sharma A, King A, Gehr T, Cotterell A, Posner MP, and Mas V
- Subjects
- Adult, Aged, Atrophy, Fibrosis, Humans, Kidney metabolism, Kidney Tubules pathology, Middle Aged, Transplantation, Homologous, Gene Expression Profiling, Kidney pathology, Kidney Transplantation adverse effects
- Abstract
Background: Loss of kidney graft function due to interstitial fibrosis (IF) and tubular atrophy (TA) is the most common cause of kidney allograft loss., Methods: One hundred one allograft tissues (26 samples with IF/TA, 17 normal allografts, and an independent biopsy group collected at 3 month [n=34] posttransplantation) underwent microarray analysis to identify early detection/diagnostic biomarkers of IF/TA. Profiling of 24 allograft biopsies collected at or after 9-month posttransplantation (range 9-18 months) was used for validation. Three-month posttransplantation biopsies were classified as IF/TA nonprogressors (group 1) or progressors (group 2) using graft function and histology at 9-month posttransplantation., Results: We identified 2223 differentially expressed probe sets between IF/TA and normal allograft biopsies using a Bonferroni correction. Genes up-regulated in IF/TA were primarily involved in pathways related to T-cell activation, natural killer cell-mediated cytotoxicity, and programmed cell death. A least absolute shrinkage and selection operator model was derived from the differentially expressed probe sets, resulting in a final model that included 10 probe sets and had 100% training set accuracy. The N-fold crossvalidated error was 2.4% (sensitivity 95.8% and specificity 100%). When 3-month biopsies were tested using the model, all the samples were classified as normal. However, evaluating gene expression of the 3-month biopsies and fitting a new penalized model, 100% sensitivity was observed in classifying the samples as group1 or 2. This model was evaluated in the sample set collected at or after 9-month posttransplantation., Conclusions: An IF/TA gene expression signature was identified, and it was useful for diagnosis but not prediction. However, gene expression profiles at 3 months might predict IF/TA progression.
- Published
- 2011
- Full Text
- View/download PDF
21. Pretransplant transcriptome profiles identify among kidneys with delayed graft function those with poorer quality and outcome.
- Author
-
Mas VR, Scian MJ, Archer KJ, Suh JL, David KG, Ren Q, Gehr TW, King AL, Posner MP, Mueller TF, and Maluf DG
- Subjects
- Adolescent, Adult, Aged, Biomarkers metabolism, Biopsy, Cohort Studies, Creatinine blood, Delayed Graft Function blood, Demography, Female, Gene Expression Regulation, Glomerular Filtration Rate physiology, Humans, Kidney pathology, Male, Middle Aged, Real-Time Polymerase Chain Reaction, Reproducibility of Results, Signal Transduction genetics, Treatment Outcome, Young Adult, Delayed Graft Function genetics, Gene Expression Profiling methods, Kidney metabolism, Kidney physiopathology, Kidney Transplantation physiology
- Abstract
Robust biomarkers are needed to identify donor kidneys with poor quality associated with inferior early and longer-term outcome. The occurrence of delayed graft function (DGF) is most often used as a clinical outcome marker to capture poor kidney quality. Gene expression profiles of 92 preimplantation biopsies were evaluated in relation to DGF and estimated glomerular filtration rate (eGFR) to identify preoperative gene transcript changes associated with short-term function. Patients were stratified into those who required dialysis during the first week (DGF group) versus those without (noDGF group) and subclassified according to 1-month eGFR of >45 mL/min (eGFR(hi)) versus eGFR of ≤45 mL/min (eGFR(lo)). The groups and subgroups were compared in relation to clinical donor and recipient variables and transcriptome-associated biological pathways. A validation set was used to confirm target genes. Donor and recipient characteristics were similar between the DGF versus noDGF groups. A total of 206 probe sets were significant between groups (P < 0.01), but the gene functional analyses failed to identify any significantly affected pathways. However, the subclassification of the DGF and noDGF groups identified 283 probe sets to be significant among groups and associated with biological pathways. Kidneys that developed postoperative DGF and sustained an impaired 1-month function (DGF(lo) group) showed a transcriptome profile of significant immune activation already preimplant. In addition, these kidneys maintained a poorer transplant function throughout the first-year posttransplant. In conclusion, DGF is a poor marker for organ quality and transplant outcome. In contrast, preimplant gene expression profiles identify "poor quality" grafts and may eventually improve organ allocation.
- Published
- 2011
- Full Text
- View/download PDF
22. Distinctive gene expression profiles characterize donor biopsies from HCV-positive kidney donors.
- Author
-
Mas VR, Archer KJ, Suh L, Scian M, Posner MP, and Maluf DG
- Subjects
- Adult, Biopsy, Case-Control Studies, Cluster Analysis, Delayed Graft Function genetics, Delayed Graft Function immunology, Female, Gene Expression Regulation, Gene Regulatory Networks, Graft Survival genetics, Hepatitis C immunology, Humans, Immunity, Innate genetics, Inflammation genetics, Kidney immunology, Male, Middle Aged, Oligonucleotide Array Sequence Analysis, Polymerase Chain Reaction, Transplantation, Homologous, Treatment Outcome, Virginia, Donor Selection, Gene Expression Profiling methods, Hepatitis C genetics, Kidney chemistry, Kidney Transplantation immunology, RNA analysis, Tissue Donors supply & distribution
- Abstract
Background: Because of the shortage of organs for transplantation, procurement of kidneys from extended criteria donors is inevitable. Frequently, donors infected with hepatitis C virus (HCV) are used. To elucidate an initial compromise of molecular pathways in HCV graft, gene expression profiles were evaluated., Methods: Twenty-four donor allograft biopsies (n=12 HCV positive (+) and n=12 HCV negative (-)) were collected at preimplantation time and profiled using microarrays. Donors were age, race, gender, and cold and warm ischemia time matched between groups. Probe level data were read into the R programming environment using the affy Bioconductor package, and the robust multiarray average method was used to obtain probe set expression summaries. To identify probe sets exhibiting differential expression, a two sample t test was performed. Molecular and biologic functions were analyzed using Interaction Networks and Functional Analysis., Results: Fifty-eight probe sets were differentially expressed between HCV (+) versus HCV (-) donors (P<0.001). The molecular functions associated with the two top scored networks from the analysis of the differentially expressed genes were connective tissue development and function and tissue morphology (score 34), cell death, cell signaling, cellular assembly, and organization (score 32). Among the differentially affected top canonical pathways, we found the role of RIG1-like receptors in antiviral innate immunity (P<0.001), natural killer cell signaling (P=0.007), interleukin-8 signaling (P=0.048), interferon signaling (P=0.0 11; INFA21, INFGR1, and MED14), ILK signaling (P=0.001), and apoptosis signaling., Conclusions: A unique gene expression pattern was identified in HCV (+) kidney grafts. Innate immune system and inflammatory pathways were the most affected.
- Published
- 2010
- Full Text
- View/download PDF
23. Living donor liver transplantation for neonatal hemochromatosis using non-anatomically resected segments II and III: a case report.
- Author
-
Sharma A, Cotterell AH, Maluf DG, Posner MP, and Fisher RA
- Abstract
Introduction: Neonatal hemochromatosis is the most common cause of liver failure and liver transplantation in the newborn. The size of the infant determines the liver volume that can be transplanted safely without incurring complications arising from a large graft. Transplantation of monosegments II or III is a standard method for the newborns with liver failure., Case Presentation: A three-week old African-American male neonate was diagnosed with acute liver failure secondary to neonatal hemochromatosis. Living-related liver transplantation was considered after the failure of intensive medical therapy. Intra-operatively a non-anatomical resection and transplantation of segments II and III was performed successfully. The boy is growing normally two years after the transplantation., Conclusion: Non-anatomical resection and transplantation of liver segments II and III is preferred to the transplantation of anatomically resected monosegements, especially when the left lobe is thin and flat. It allows the use of a reduced-size donor liver with intact hilar structures and outflow veins. In an emergency, living-related liver transplantation should be offered to infants with liver failure secondary to neonatal hemochromatosis who fail to respond to medical treatment.
- Published
- 2010
- Full Text
- View/download PDF
24. Saphenous vein graft aneurysm after renal transplantation: a case report.
- Author
-
Sharma A, King AL, Lee HM, and Posner MP
- Subjects
- Adult, Creatinine blood, Glomerulosclerosis, Focal Segmental complications, Graft Rejection surgery, Humans, Iliac Artery surgery, Kidney Failure, Chronic etiology, Male, Postoperative Complications, Plastic Surgery Procedures, Reoperation, Saphenous Vein surgery, Treatment Outcome, Aneurysm diagnosis, Kidney Failure, Chronic surgery, Kidney Transplantation adverse effects, Saphenous Vein transplantation
- Published
- 2010
- Full Text
- View/download PDF
25. Adult living donor versus deceased donor liver transplantation: a 10-year prospective single center experience.
- Author
-
Fisher RA, Cotterell AH, Maluf DG, Stravitz RT, Ashworth A, Nakatsuka M, Sterling RK, Luketic VA, Behnke MK, and Posner MP
- Subjects
- Adult, Cold Ischemia, Female, Follow-Up Studies, Humans, Immunosuppressive Agents therapeutic use, Kaplan-Meier Estimate, Liver Transplantation immunology, Liver Transplantation mortality, Longitudinal Studies, Male, Middle Aged, Postoperative Complications, Prospective Studies, Retrospective Studies, Treatment Outcome, Waiting Lists, Graft Survival physiology, Hepatitis C surgery, Liver Transplantation physiology, Living Donors, Tissue Donors
- Abstract
It has been 4 years since the first, long-term (> 3 years) prospective comparison of adult-to-adult living donor liver transplantation (A2ALLTx) to adult deceased donor liver transplantation (ADDLTx) was reported. In this follow up, prospective, IRB approved, 10-year comparison of A2ALLTx to ADDLTx we expand on our initial observations. This data includes: age, gender, ethnicity, primary liver disease, waiting time, pretransplant CTP/MELD score, cold ischemia time (CIT), perioperative mortality, acute and chronic rejection, graft and patient survival, charges and post-transplant complications. In 10 years, 465 ADDLTx (81.3%) and 107 A2ALLTx (18.7%) were performed at VCUHS. Hepatitis C virus (HCV) was the most common reason for transplantation in both groups (54.5% vs. 48.2%). Data regarding overall patient and graft survival and retransplantation rates were similar. Comparison of patient/graft survivals, retransplantation rates in patients with and without HCV were not statistically different. A2ALLTx patients had less acute rejection (9.6% vs. 21.7%) and more biliary complications (27.1% vs. 17.6%). In conclusion, A2ALLTx is as durable a liver replacement technique as the ADDLTx. Patients with A2ALLTx were younger, had lower MELD scores, less acute rejection and similar histological HCV recurrence. Biliary complications were more common in A2ALLTx but were not associated with increased graft loss compared to ADDLTx.
- Published
- 2009
26. Effect of hyponatraemia on outcomes following orthotopic liver transplantation.
- Author
-
Hackworth WA, Heuman DM, Sanyal AJ, Fisher RA, Sterling RK, Luketic VA, Shiffman ML, Maluf DG, Cotterell AH, Posner MP, and Stravitz RT
- Subjects
- Adolescent, Adult, Aged, Critical Care, Female, Humans, Hyponatremia blood, Hyponatremia mortality, Kaplan-Meier Estimate, Length of Stay, Liver Cirrhosis complications, Liver Cirrhosis mortality, Liver Transplantation mortality, Male, Middle Aged, Patient Discharge, Proportional Hazards Models, Respiration, Artificial, Retrospective Studies, Risk Assessment, Risk Factors, Sodium blood, Time Factors, Treatment Outcome, Young Adult, Hyponatremia complications, Liver Cirrhosis surgery, Liver Transplantation adverse effects
- Abstract
Background: Hyponatraemia increases risk of adverse outcomes following orthotopic liver transplantation (OLT), but it is unclear whether improvement of pretransplant hyponatraemia ameliorates post-transplant complications., Aims: To assess impact of pretransplant hyponatraemia on post-transplant outcomes., Methods: We performed a retrospective analysis of 213 patients with cirrhosis who underwent liver transplantation. Patients with serum sodium
130 mEq/L at transplantation ('resolved hyponatraemia'; n=56) and to those without history of hyponatraemia before transplantation ('never hyponatraemic'; n=123). Primary endpoint was survival at 180 days post-OLT. Secondary outcomes included time until discharge alive, complications during hospitalization, length of time ventilated and length of post-transplant intensive care unit stay., Results: There was no survival difference at 180 days post-OLT between groups. After transplantation, patients with either hyponatraemia at OLT or resolved hyponatraemia had longer time until discharge alive and had higher rates of delirium, acute renal failure, acute cellular rejection and infection than those who were never hyponatraemic. As compared with patients with hyponatraemia at OLT, those with resolved hyponatraemia were more likely to be discharged alive within 3 weeks, but other outcomes, including survival, did not differ significantly., Conclusions: We conclude that hyponatraemia at any time before liver transplantation is associated with adverse post-transplant outcome, even when hyponatraemia has resolved. - Published
- 2009
- Full Text
- View/download PDF
27. Incidence of prolonged length of stay after orthotopic liver transplantation and its influence on outcomes.
- Author
-
Smith JO, Shiffman ML, Behnke M, Stravitz RT, Luketic VA, Sanyal AJ, Heuman DM, Fisher RA, Cotterell AH, Maluf DG, Posner MP, and Sterling RK
- Subjects
- Adult, Female, Graft Survival, Humans, Liver Transplantation mortality, Liver Transplantation physiology, Male, Middle Aged, Patient Selection, Regression Analysis, Reoperation statistics & numerical data, Retrospective Studies, Survival Rate, Survivors, Treatment Outcome, Virginia, Length of Stay statistics & numerical data, Liver Transplantation statistics & numerical data
- Abstract
Orthotopic liver transplantation (OLT) is the only effective treatment for end-stage liver disease. Although most patients do well and are discharged promptly, some require prolonged length of stay (PLOS). The prevalence of PLOS, associated factors, and their impact on survival are not well defined. We reviewed our adult OLT database for patients who survived > 30 days. PLOS was defined as hospitalization > 30 days following OLT. Of 521 OLT recipients, 68 (13%) had PLOS with a median duration of 50 days versus only 10 days for patients discharged within 30 days. Significant differences in pre-OLT variables between patients with and without PLOS included the mean wait list time (P = 0.001), hospitalization at the time of OLT (P = 0.001), and prior OLT (P = 0.041). Factors independently associated with PLOS included intensive care unit status at the time of OLT [odds ratio (OR), 4; 95% confidence interval (CI), 1.6-10.4], OLT prior to Model for End-Stage Liver Disease implementation (OR, 2.27; 95% CI, 1.04-5.26), in-hospital post-OLT bacterial infection (OR, 9.34; 95% CI, 4.65-18.86), gastrointestinal bleeding (OR, 4.34; 95% CI, 1.4-14.08), renal failure (OR, 10.86; 95% CI, 5.07-23.25), and allograft rejection (OR, 3.7; 95% CI, 1.23-11.11). One-year graft survival and patient survival were significantly less in those with PLOS (for both, P < 0.0001). Among PLOS patients, factors independently associated with increased 1-year mortality were donor age (OR, 1.07; 95% CI, 1.009-1.13), primary diagnosis of hepatitis C virus (OR, 6.89; 95% CI, 1.40-34.48), in-hospital post-OLT bacterial infection (OR, 13.3; 95% CI, 2.11-83.33), and cardiac complications (OR, 20.4; 95% CI, 1.51-250; c-statistic for the model, 0.85). In conclusion, PLOS following OLT is associated with a significant decrease in survival despite a marked increase in cost and resource utilization. Efforts to modify those factors that contribute to PLOS may reduce this event, improve survival, and reduce OLT-associated costs.
- Published
- 2009
- Full Text
- View/download PDF
28. Molecular pathways involved in loss of kidney graft function with tubular atrophy and interstitial fibrosis.
- Author
-
Maluf DG, Mas VR, Archer KJ, Yanek K, Gibney EM, King AL, Cotterell A, Fisher RA, and Posner MP
- Subjects
- Adult, Animals, Chemokine CCL5 blood, Chemokine CCL5 genetics, Chemokine CCL5 metabolism, Chemokines blood, Chemokines genetics, Chemokines metabolism, Female, Fibrosis, Gene Expression Profiling, Graft Rejection genetics, Graft Rejection metabolism, Humans, Kidney pathology, Kidney physiopathology, Kidney Diseases etiology, Kidney Diseases genetics, Kidney Transplantation adverse effects, Male, Middle Aged, Oligonucleotide Array Sequence Analysis, Receptors, CXCR blood, Receptors, CXCR genetics, Receptors, CXCR metabolism, Receptors, CXCR4 blood, Receptors, CXCR4 genetics, Receptors, CXCR4 metabolism, Receptors, Chemokine blood, Receptors, Chemokine genetics, Receptors, Chemokine metabolism, Receptors, Interleukin blood, Receptors, Interleukin genetics, Receptors, Interleukin metabolism, Graft Rejection blood, Kidney metabolism, Kidney Diseases blood, Kidney Transplantation methods
- Abstract
Loss of kidney graft function with tubular atrophy (TA) and interstitial fibrosis (IF) causes most kidney allograft losses. We aimed to identify the molecular pathways involved in IF/TA progression. Kidney biopsies from normal kidneys (n = 24), normal allografts (n = 6), and allografts with IF/TA (n = 17) were analyzed using high-density oligonucleotide microarray. Probe set level tests of hypotheses tests were conducted to identify genes with a significant trend in gene expression across the three groups using Jonckheere-Terpstra test for trend. Interaction networks and functional analysis were used. An unsupervised hierarchical clustering analysis showed that all the IF/TA samples were associated with high correlation. Gene ontology classified the differentially expressed genes as related to immune response, inflammation, and matrix deposition. Chemokines (CX), CX receptor (for example, CCL5 and CXCR4), interleukin, and interleukin receptor (for example, IL-8 and IL10RA) genes were overexpressed in IF/TA samples compared with normal allografts and normal kidneys. Genes involved in apoptosis (for example, CASP4 and CASP5) were importantly overexpressed in IF/TA. Genes related to angiogenesis (for example, ANGPTL3, ANGPT2, and VEGF) were downregulated in IF/TA. Genes related to matrix production-deposition were upregulated in IF/TA. A distinctive gene expression pattern was observed in IF/TA samples compared with normal allografts and normal kidneys. We were able to establish a trend in gene expression for genes involved in different pathways among the studied groups. The top-scored networks were related to immune response, inflammation, and cell-to-cell interaction, showing the importance of chronic inflammation in progressive graft deterioration.
- Published
- 2008
- Full Text
- View/download PDF
29. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome.
- Author
-
Stravitz RT, Heuman DM, Chand N, Sterling RK, Shiffman ML, Luketic VA, Sanyal AJ, Habib A, Mihas AA, Giles HC, Maluf DG, Cotterell AH, Posner MP, and Fisher RA
- Subjects
- Female, Humans, Liver Cirrhosis surgery, Liver Transplantation, Male, Middle Aged, Outcome and Process Assessment, Health Care, Prognosis, Quality of Health Care, Retrospective Studies, Carcinoma, Hepatocellular diagnosis, Carcinoma, Hepatocellular etiology, Liver Cirrhosis complications, Liver Neoplasms diagnosis, Liver Neoplasms etiology, Mass Screening methods
- Abstract
Objective: Liver transplantation has become an effective treatment for cirrhotic patients with early-stage hepatocellular carcinoma. We hypothesized that the quality of surveillance for hepatocellular carcinoma influences prognosis by affecting access to liver transplantation., Methods: A total of 269 patients with cirrhosis and hepatocellular carcinoma were retrospectively categorized into 3 groups according to quality of surveillance: standard-of-care (n=172) (group 1); substandard surveillance (n=48) (group 2); and absence of surveillance in patients not recognized to be cirrhotic (n=59) (group 3)., Results: Three-year survival in the 60 patients who underwent liver transplantation was 81% versus 12% for patients who did not undergo transplantation (P<.001). The percentages of patients who underwent transplantation according to tumor stage at diagnosis (T1, T2, T3, and T4) were 58%, 35%, 10%, and 1%, respectively. Hepatocellular carcinoma was diagnosed at stages 1 and 2 in 70% of patients in group 1, 37% of patients in group 2, and only 18% of patients in group 3 (P <.001). Liver transplantation was performed in 32% of patients in group 1, 13% of patients in group 2, and 7% of patients in group 3 (P<.001). Three-year survival from cancer diagnosis in patients in group 3 (12%) was significantly worse than in patients in group 1 (39%) or group 2 (27%) (each P<.05). Eighty percent of patients in group 3 had subtle abnormalities of cirrhosis on routine laboratory tests., Conclusion: The quality of surveillance has a direct impact on hepatocellular carcinoma stage at diagnosis, access to liver transplantation, and survival.
- Published
- 2008
- Full Text
- View/download PDF
30. Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years.
- Author
-
Yilmaz N, Shiffman ML, Todd Stravitz R, Sterling RK, Luketic VA, Sanyal AJ, Maluf D, Coterell A, Posner MP, and Fisher RA
- Subjects
- Adenine analogs & derivatives, Adenine therapeutic use, Adult, Dose-Response Relationship, Drug, Female, Hepatitis B e Antigens blood, Humans, Lamivudine therapeutic use, Male, Middle Aged, Organophosphonates therapeutic use, Retrospective Studies, Secondary Prevention, Virginia, Antiviral Agents therapeutic use, Hepatitis B prevention & control, Hepatitis B surgery, Immunoglobulins therapeutic use, Liver Transplantation
- Abstract
Liver transplantation (LT) in patients with hepatitis B virus (HBV) infection is associated with a high rate of graft loss and poor survival, unless re-infection can be prevented. Human hepatitis B immune globulin (HBIG) has long been utilized to prevent re-infection. More recently, an anti-viral agent has been utilized along with HBIG. However, the regimens utilized have varied considerably among LT programmes and the optimal regimen has never been defined. We conducted a retrospective analysis of 41 patients who underwent LT for HBV at our centre since 1985 and received either HBIG with or without an anti-viral agent. The mean age of these patients was 46 years; 81% were male and 88% white. The mean and maximal follow-up were 5.9 and 15 years respectively. Eight out of 15 E-antigen-positive patients who received HBIG alone developed recurrence after a mean of 17 months. In contrast, none of 10 E-Ag-negative patients who received HBIG alone and none of the 10 E-antigen-positive patients who received both HBIG and either lamivudine or adefovir developed recurrence. As long as the anti-HB surface remained detectable, no absolute minimum serum level appeared to lead to recurrent HBV. We concluded that recurrence of HBV following LT can be prevented in E-antigen-positive patients with a combination of HBIG and an anti-viral agent. In contrast, recurrence can be prevented in E-antigen-negative patients with HBIG alone. Maintaining a serum anti-HB surface level above a minimum arbitrary titre of 200 pg/mL did not appear to be necessary for effective HBIG prophylaxis.
- Published
- 2008
- Full Text
- View/download PDF
31. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation.
- Author
-
Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, Sanyal AJ, Mills AS, Contos MJ, Coterell A, Maluf D, Posner MP, and Fisher RA
- Subjects
- Adult, Antiviral Agents therapeutic use, Fatty Liver classification, Fatty Liver pathology, Female, Genotype, Hepacivirus genetics, Hepacivirus isolation & purification, Hepatitis C drug therapy, Humans, Male, Middle Aged, Polymerase Chain Reaction, Prospective Studies, RNA, Viral genetics, RNA, Viral isolation & purification, Recurrence, Retrospective Studies, Transplantation, Homologous, Viral Load, Fatty Liver epidemiology, Hepatitis C pathology, Hepatitis C surgery, Liver Transplantation adverse effects, Liver Transplantation pathology
- Abstract
Recurrence of hepatitis C virus (HCV) following liver transplantation (LT) is universal. A subset of these patients develop advanced fibrosis and cirrhosis and it is believed that this leads to increased posttransplantation mortality. The specific aims of this study were to determine the incidence of advanced fibrosis and those factors associated with this process, and to evaluate causes for mortality in patients with recurrent HCV. A total of 227 patients who underwent LT with chronic HCV were monitored prospectively. The mean age of this group at LT was 49.5 yr; 76% were male and 85% were Caucasian. Fibrosis progression was monitored by protocol liver biopsy, initially performed 6 months after LT and then at 6- to 24-month intervals. Advanced fibrosis, defined as the bridging fibrosis or cirrhosis, developed in 1%, 11%, 25%, and 41% of patients after 1, 3, 5, and 6-10 yr, respectively. Acute cellular rejection hepatic steatosis, a persistent elevation in serum alanine aminotransferase and donor-race were associated with the development of advanced fibrosis. In contrast, the development of advanced fibrosis was not affected by the use of interferon prior to undergoing LT, cytomegalovirus disease, or donor age. A total of 60 patients (26%) died over 15 yr of follow-up. Although graft failure accounted for 45% of deaths in patients with advanced fibrosis, this represented only 8% of all deaths in patients with recurrent HCV. Sepsis was the most common cause of death and this was observed with similar frequency in patients who developed advanced fibrosis (45%) and in those with less advanced fibrosis (47%). In conclusion, approximately 41% of patients with recurrent HCV developed advanced fibrosis 6-10 yr after LT. However, complications associated with sepsis, not recurrent cirrhosis, was the most common cause of death in patients with recurrent HCV and this was similar in patients with or without advanced fibrosis.
- Published
- 2007
- Full Text
- View/download PDF
32. Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival.
- Author
-
Maluf DG, Fisher RA, King AL, Gibney EM, Mas VR, Cotterell AH, Shiffman ML, Sterling RK, Behnke M, and Posner MP
- Subjects
- Biopsy, Cadaver, Female, Fish Oils therapeutic use, Humans, Liver pathology, Liver virology, Living Donors, Male, Middle Aged, Tissue Donors, Treatment Outcome, Triglycerides blood, Graft Survival physiology, Hepatitis C complications, Kidney Failure, Chronic complications, Kidney Failure, Chronic surgery, Kidney Transplantation physiology
- Abstract
Background: The effect of hepatitis C virus (HCV) infection on patients undergoing kidney transplantation (KTx) is uncertain. This study aimed to evaluate the outcomes of our HCV+/end-stage renal disease (ESRD) patient population based on the therapeutic option including KTx or continuation in dialysis., Methods: KTx performed at Virginia Commonwealth University Hospital between January 2000 and December 2004 were tracked prospectively. Forty-three out of a total of 394 KTx patients included in the analysis were HCV+. A group of 52 contemporaneous HCV+/ESRD patients listed, but never transplanted, was also analyzed. HCV-negative transplanted patients were used as the control group., Results: Patient survival posttransplantation was 81.4% and 68.5% at 1 and 3 years in the HCV+ group, and 97.1% and 92.9% at 1 and 3 years in the HCV- group, respectively (P=0.001). Graft survival was 81.2% and 64.1% at 1 and 3 years in the HCV+ group, and 93.2% and 84.1% at 1 and 3 years posttransplantation in the HCV- group (P=0.01). Univariate analysis identified Knodell score as a predictor of mortality in HCV+ patients (P=0.04). Cox proportional hazards multivariate analysis identified deceased donor (P=0.02), previous kidney transplant (P=0.007), pretransplant diabetes (P=0.05), and Knodell Score (P=0.012) as predictors of patient mortality. Patient survival was superior in HCV+ patients undergoing KTx versus remaining on dialysis., Conclusions: Patients with ESRD/HCV+ benefit from KTx without achieving the excellent survival of HCV-/ESRD patients. Liver biopsy is a useful tool to identify advanced liver disease at pretransplantation time.
- Published
- 2007
- Full Text
- View/download PDF
33. Multimodality therapy and liver transplantation in patients with cirrhosis and hepatocellular carcinoma: 6 years, single-center experience.
- Author
-
Maluf DG, Stravitz RT, Williams B, Cotterell AH, Mas VR, Heuman D, Luketic V, Shiffman ML, Sterling R, Posner MP, and Fisher RA
- Subjects
- Adult, Carcinoma, Hepatocellular pathology, Combined Modality Therapy, Female, Hepatitis B surgery, Humans, Male, Middle Aged, Neoplasm Staging, Recurrence, Retrospective Studies, Treatment Outcome, Carcinoma, Hepatocellular surgery, Liver Cirrhosis surgery, Liver Transplantation pathology, Liver Transplantation statistics & numerical data
- Abstract
The treatment of patients with cirrhosis and hepatocellular carcinoma (HCC) has improved dramatically over the past 10 years. We conducted a 6-year prospective study, using multimodality ablation therapy (MMT) combined with liver transplantation (LTx) for patients with cirrhosis and unresectable HCC. Subjects were classified as: group 1 (n = 35), intention to treat with MMT + LTx; group 2 (n = 16), contemporaneous LTx with "incidental" HCC on explants; group 3 (n = 94), MMT alone; and group 4 (n = 19), palliative care alone. MMT included trans-arterial chemo-embolization (54.4%), trans-arterial chemo-infusion (28.6%), and radio frequency ablation (17%). Group 1, with a mean wait time of 11.6 months pre-MELD era and 5.4 months post-MELD era, had a mean of 2.4 +/- 1.2 MMTs and achieved 1- 3-, and 5-year patient survivals of 100, 100, and 76%, respectively, which was not different from group 2 (incidental HCC), namely 93, 93, and 93%, respectively; or to a contemporaneous non-HCC LTx group: namely 84.3, 78.7, and 73.9%, respectively. Despite careful pretransplant HCC staging, 22.8% (8 of 35) group 1 subjects were understaged. Those subjects in group 1 with true T1-2 stage HCC achieved 100% cancer-free survival at 5 years. Only three cases of HCC recurrence occurred in our series, all of whom were understaged. Our data suggest that pretransplant MMT followed by timely LTx provides excellent disease-free survival at 5 years for patients with true T1-2 stage HCC and cirrhosis. Pretransplant HCC understaging contributes to posttransplant HCC recurrence after LTx.
- Published
- 2007
- Full Text
- View/download PDF
34. Molecular markers in stored kidneys using perfluorocarbon-based preservation solution: preliminary results.
- Author
-
Maluf DG, Mas VR, Yanek K, Stone JJ, Weis R, Massey D, Spiess B, Posner MP, and Fisher RA
- Subjects
- Adenosine, Allopurinol, Animals, Biomarkers, Gene Expression Regulation, Glutathione, Heme Oxygenase-1 genetics, Insulin, Male, Models, Animal, Nitric Oxide Synthase Type II genetics, Raffinose, Rats, Rats, Inbred ACI, Fluorocarbons pharmacology, Kidney drug effects, Kidney physiology, Organ Preservation Solutions, RNA, Messenger genetics
- Abstract
Background: Delayed graft function (DGF) is a problem in kidney transplantation and cold ischemia has been identified as a risk factor. Perfluorocarbons (PFC) have an enhanced ability to dissolve and release oxygen. We evaluated histologically and a number of molecular changes induced by ischemia in stored kidneys with University of Wisconsin (UW) and PFC-based preservation solutions (PFC-UW)., Materials and Methods: ACI rats were used as kidney donors. UW (control group) or PFC-UW (study group) preservation solutions were used for kidney perfusion. All kidneys were stored at 4 degrees C for 12, 24, and 36 hours. After this time, intragraft histologic evaluation as well as mRNA HO-1 and iNOS levels were also analyzed., Results: In the kidneys stored at 24 hours, mRNA HO-1 levels were elevated in the study group when compared with the control and mRNA iNOS was decreased., Conclusion: We observed overexpression of HO-1 and underexpression of iNOS in the kidney tissue stored with PFC-UW solution at 24 hours. These preliminary data suggest that increasing oxygen delivery by PFC added to the perfusion solution triggers cytoprotective mechanism in kidney transplantation.
- Published
- 2006
- Full Text
- View/download PDF
35. Adult living donor versus deceased donor liver transplantation: a 6-year single center experience.
- Author
-
Maluf DG, Stravitz RT, Cotterell AH, Posner MP, Nakatsuka M, Sterling RK, Luketic VA, Shiffman ML, Ham JM, Marcos A, Behnke MK, and Fisher RA
- Subjects
- Adult, Aged, Biopsy, Cadaver, Cold Temperature, Female, Graft Survival, Hepacivirus metabolism, Hepatitis C mortality, Hepatitis C pathology, Hepatitis C therapy, Humans, Immunosuppressive Agents pharmacology, Ischemia, Liver, Liver Diseases etiology, Liver Failure therapy, Living Donors, Male, Middle Aged, Proportional Hazards Models, Prospective Studies, Recurrence, Time Factors, Tissue Donors, Tissue and Organ Procurement methods, Liver Transplantation methods
- Abstract
No long-term (>3 years) prospective comparison of adult-to-adult living donor liver transplantation (A2ALLTx) to adult deceased donor liver transplantation (ADDLTx) has been reported. This is a prospective, IRB approved, 6-year comparison of A2ALLTx to ADDLTx. Data include: age, gender, ethnicity, primary liver disease, waiting time, pretransplant CTP/MELD score, cold ischemia time (CIT), perioperative mortality, acute and chronic rejection, graft and patient survival, charges and post-transplant complications. In 6 years, 202 ADDLTx (74.5%) and 69 A2ALLTx (25.5%) were performed at VCUHS. Hepatitis C virus (HCV) was the most common reason for transplantation in both groups (48.1% vs. 42%). Data regarding overall patient and graft survival, monetary charges and retransplantation rates were similar. Comparison of patient/graft survivals, retransplantation rates in patients with and without HCV were not statistically different. A2ALLTx patients had less acute rejection (11.5% vs. 23.9%) and more biliary complications (26.1% vs. 11.4%). Overall, A2ALLTx is as durable a liver replacement technique as the ADDLTx. Patients with A2ALLTx were younger, had lower MELD scores, less acute rejection and similar histological HCV recurrence. Biliary complications were more common in A2ALLTx but were not associated with increased graft loss compared to ADDLTx.
- Published
- 2005
- Full Text
- View/download PDF
36. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation.
- Author
-
Shiffman ML, Stravitz RT, Contos MJ, Mills AS, Sterling RK, Luketic VA, Sanyal AJ, Cotterell A, Maluf D, Posner MP, and Fisher RA
- Subjects
- Adult, Biopsy, Needle, Cadaver, Female, Hepatitis C, Chronic surgery, Humans, Male, Middle Aged, Prospective Studies, Recurrence, Hepatitis C, Chronic pathology, Liver Transplantation methods, Living Donors
- Abstract
Hepatitis C virus (HCV) recurs in nearly all patients after liver transplantation. This recurrence is associated with progressive fibrosis and graft loss. It remains unclear whether the natural course of HCV recurrence is altered in patients who undergo living donor liver transplantation (LDLT). We conducted a prospective, controlled trial using protocol liver biopsies to evaluate the histologic outcome of recurrent HCV in 23 patients who underwent LDLT and 53 patients who underwent transplantation with a deceased donor liver (DDLT) during the same period of time. Patients who did not survive at least 6 months after transplantation or who had hepatocellular carcinoma or any other coexistent liver disease were excluded from analysis. All patients underwent protocol liver biopsy at 6 months and at 12 months and at yearly intervals thereafter. The mean age, sex, racial distribution, and serum HCV RNA and the percentage of patients with genotype 1 were similar in the 2 groups of patients. The model for end-stage liver disease score at the time of transplantation was slightly lower in patients who underwent LDLT, but this difference was not significant. The distribution of immunosuppression agents used, the mean doses of calcineurin agents, the use of mycophenolate mofetil, and the dose and tapering schedule for prednisone were similar in both groups of patients. The mean duration of follow-up was 40 months. No significant difference in either graft or patient survival or the percentage of patients who developed acute rejection was noted in the 2 groups of patients. At 48 months, graft and patient survival were 82% and 82% and 75% and 79% for patients who underwent DDLT and LDLT, respectively. The degree of hepatic inflammation increased stepwise over 3 years but was not significantly different in the 2 patient groups. In contrast, the mean fibrosis score and the percentage of patients with fibrosis increased stepwise after DDLT but appeared to plateau 12 months after LDLT. At 36 months, fibrosis was present in 78% of DDLT patients, and mean fibrosis score was 1.9, compared with 59% with fibrosis and a mean score of.9 after LDLT. In conclusion, these data strongly suggest that fibrosis progression from recurrent HCV is not more severe in patients after LDLT.
- Published
- 2004
- Full Text
- View/download PDF
37. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
- Author
-
Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML, Sterling RK, Shiffman ML, Luketic VA, Contos MJ, Mills AS, Ferreira-Gonzalez A, and Posner MP
- Subjects
- Drug Therapy, Combination, Emulsions, Female, Follow-Up Studies, Graft Survival, Humans, Liver Cirrhosis surgery, Liver Cirrhosis virology, Liver Function Tests, Male, Middle Aged, Patient Readmission statistics & numerical data, Prospective Studies, Remission Induction, Cyclosporine therapeutic use, Graft Rejection prevention & control, Immunosuppressive Agents therapeutic use, Liver Transplantation, Mycophenolic Acid analogs & derivatives, Mycophenolic Acid therapeutic use, Tacrolimus therapeutic use
- Abstract
Background: This is a 4-yr follow-up of a trial using mycophenolate mofetil (MMF) induction in orthotopic liver transplantation (OLT). The goal of this study was to evaluate a multidrug approach that would reduce both early and long-term morbidity related to immunosuppression while maintaining an acceptable freedom from rejection., Methods: This was a prospective, randomized, intent to treat study designed to compare the primary endpoints of rejection and infection, and secondary endpoints of liver function, renal function, bone marrow function, cardiovascular risk factors, and the recurrence of hepatitis C. Ninety-nine consecutive patients with end stage liver disease who underwent OLT were randomized to receive either cyclosporine microemulsion (N) (50 patients) or tacrolimus (FK) (49 patients) starting on postoperative day 2, with MMF and an identical steroid taper begun preoperatively., Results: Ninety of 99 patients (N 46, FK 44) completed the 4-yr follow-up. The overall 4-yr patient and graft survivals were 93 and 89%, respectively. There was no significant difference in 4-yr patient (N 96% vs. FK 90%, p = ns) or graft (N, 90% vs. FK, 88%, p = ns) survival between groups. The 4-yr rejection rate was not significantly different in either arm (N = 34%, FK = 24%; p = 0.28). There were no differences in infection rates in either arm. The patients with hepatitis C had no differences in the viral titers or Knodell biopsy scores between groups. However, in the hepatitis C subgroup (37 patients), the FK patients had a significantly lower rejection rate (p = 0.0097) and a significantly lower clinically recurrent hepatitis C rate (p = 0.05) than the N patients. No difference was seen in the percent of patients weaned off of steroids after 4 yr (N 51%, FK 49%). There were no differences in the incidences of diabetes mellitus and hypertension. When renal dysfunction was analyzed, a significant difference in the number of patients whose creatinine had increased twofold since transplant was seen (N 63%, FK 38%, p = 0.04)., Conclusions: Use of MMF induction and maintenance following OLT in conjunction with either N or FK and an identical steroid taper, resulted in an acceptable long-term incidence of rejection and infection, without an increase in long-term graft or patient morbidity.
- Published
- 2004
- Full Text
- View/download PDF
38. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
- Author
-
Stravitz RT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Heuman DM, Ashworth A, Mills AS, Contos M, Cotterell AH, Maluf D, Posner MP, and Fisher RA
- Subjects
- Adult, Biopsy, Genotype, Graft Rejection pathology, Graft Rejection prevention & control, Hepacivirus genetics, Hepacivirus isolation & purification, Hepatitis C drug therapy, Humans, Immunosuppressive Agents classification, Immunosuppressive Agents therapeutic use, Interferon alpha-2, Interferon-alpha therapeutic use, Middle Aged, RNA, Viral blood, RNA, Viral isolation & purification, Recombinant Proteins, Recurrence, Retrospective Studies, Ribavirin therapeutic use, Transplantation, Homologous pathology, Antiviral Agents therapeutic use, Graft Rejection epidemiology, Hepatitis C surgery, Interferons therapeutic use, Liver Transplantation pathology
- Abstract
Recurrent hepatitis C after liver transplantation remains a significant cause of graft loss and retransplantation. Although treatment of recurrent hepatitis C with interferon-based regimens has become widely accepted as safe and can lead to sustained virologic clearance of hepatitis C virus (HCV) RNA, long-term histologic improvement and the risk of precipitating graft rejection remain controversial. The present study is a retrospective evaluation of the clinical and histological consequences of treating recurrent hepatitis C with interferon-based therapy in a selected group of liver transplant recipients. Twenty-three liver transplant recipients with recurrent hepatitis C and histologic evidence of progressive fibrosis completed at least 6 months of interferon, 83% of whom received pegylated-interferon alpha-2b; only 4 tolerated ribavirin. Overall, 11 patients (48%) had undetectable HCV RNA at the end of 6 months of treatment. Of these patients, 3 remained HCV RNA-negative on maintenance interferon monotherapy for 33 months, and the other 8 (35%) completed treatment and remained HCV RNA-undetectable 24 weeks after discontinuation of interferon. Overall necroinflammatory activity in liver biopsies obtained 2 years after HCV RNA became undetectable decreased significantly (7.73 +/- 2.37 vs. 5.64 +/- 2.94 units before and after treatment, respectively; P =.016). However, 5 of these 11 patients had no histologic improvement in follow-up liver histology. Liver biopsies in the 12 nonresponders demonstrated disease progression. Of the 23 patients treated with interferon, 8 (35%) had evidence of acute or chronic rejection on posttreatment liver biopsy, most of whom had no previous history of rejection (P <.01 for comparison of pretreatment and posttreatment prevalence of histologic rejection), and 2 experienced graft loss from chronic rejection, requiring retransplantation. In conclusion, interferon treatment of recurrent hepatitis C does not consistently improve histologic disease after virologic response, and it may increase the risk of allograft rejection.
- Published
- 2004
- Full Text
- View/download PDF
39. Massive hepatic artery atherosclerosis of an otherwise suitable donor liver: a case report.
- Author
-
Maluf D, Clark BD, Cotterell AH, Posner MP, and Fisher RA
- Subjects
- Aorta, Abdominal pathology, Brain Death, Female, Hepatectomy methods, Humans, Middle Aged, Tissue and Organ Harvesting methods, Arteriosclerosis pathology, Arteriosclerosis surgery, Hepatic Artery pathology, Hepatic Artery surgery, Liver Transplantation methods
- Abstract
Most of the few reports about hepatic artery disease found in the literature describe hepatic artery aneurysms or hepatic artery calcifications. Atherosclerosis of the hepatic artery is not commonly evaluated during deceased donor liver procurement. Herein we present a case of a stable 47-year-old Caucasian female donor whose liver function tests were within normal limits and a liver biopsy showed less than 5% steatosis. The liver when received at our center appeared grossly unremarkable. Back-table evaluation showed a complete occlusion of the trunk of the proper hepatic artery. The pathology report revealed hepatic occlusion due to arterial atherosclerosis. Transplantation was canceled, and the liver was used for isolated hepatocyte perfusion, revealing < 25% hepatocyte viability. Hepatic artery atherosclerosis and patency need to be evaluated at the time of procurement to prevent recipient morbidity due to anesthetic induction, or initiation of a recipient abdominal incision prior to declining the liver graft for this rare finding., (Copyright 2004 Elsevier Inc.)
- Published
- 2004
- Full Text
- View/download PDF
40. Reasons for non-use of recovered kidneys: the effect of donor glomerulosclerosis and creatinine clearance on graft survival.
- Author
-
Edwards EB, Posner MP, Maluf DG, and Kauffman HM
- Subjects
- Aged, Aged, 80 and over, Biopsy, Cadaver, Cohort Studies, Female, Glomerulosclerosis, Focal Segmental pathology, Humans, Kidney metabolism, Kidney Transplantation standards, Kidney Transplantation statistics & numerical data, Male, Middle Aged, Multivariate Analysis, Outcome Assessment, Health Care, Predictive Value of Tests, Registries, Tissue and Organ Procurement, Creatinine metabolism, Glomerulosclerosis, Focal Segmental mortality, Graft Survival, Kidney pathology, Kidney Transplantation mortality
- Abstract
Background: In 2000, the United Network for Organ Sharing/Organ Procurement and Transplantation Network Registry reported 540 recovered kidneys were discarded because of biopsy results, and 210 were discarded because of poor organ function. We compared the percentage of glomerulosclerosis (GS) and creatinine clearance (CrCl) of both discarded and transplanted cadaveric kidneys and examined their effect on graft survival and function., Methods: The cohort consisted of all cadaveric kidneys (n= 3,444) with reported biopsy results between October 25, 1999 and December 31, 2001. Graft survival was calculated by univariate and multivariate models., Results: Fifty-one percent of discarded kidneys had GS of less than 20%, 27% had a CrCl greater than 80 mL/min, and 15% (129 kidneys) had both GS less than 20% and a CrCl of greater than 80 mL/min. Univariate analyses of kidneys with less than or equal to 20% GS revealed no difference in 1-year graft survival when the CrCl was greater than or less than or equal to 80 mL/min. When GS was greater than 20%, 1-year graft survival of kidneys with a CrCl of greater than 80 mL/min was significantly greater than that of kidneys with a CrCl of less than or equal to 80 mL/min. Multivariate results showed no significant difference in relative risk of graft loss with GS greater than 20% versus less than or equal to 20% when the CrCl was either 50 or 80 mL/min. With both GS less than or equal to 20% and greater than 20%, serum creatinine at 1 year was significantly lower in kidneys with CrCl greater 80 mL/min., Conclusions: Calculated donor CrCl does, and percentage GS on donor kidney biopsies does not, correlate well with 1-year graft survival and function, and percentage GS should not be used as the sole criterion for discarding recovered cadaveric kidneys.
- Published
- 2004
- Full Text
- View/download PDF
41. Hardikar syndrome: a case requiring liver transplantation.
- Author
-
Maluf DG, Fisher RA, Fulcher AS, and Posner MP
- Subjects
- Child, Preschool, Female, Humans, Liver pathology, Liver Diseases diagnosis, Magnetic Resonance Imaging, Syndrome, Abnormalities, Multiple, Hydronephrosis complications, Liver Diseases complications, Liver Diseases surgery, Liver Transplantation, Retinal Diseases complications
- Abstract
We report the case of a girl with Hardikar syndrome who underwent living-donor liver transplantation at 2 years of age. This disease, described in 1992, includes a constellation of abnormalities, such as cleft lip and palate, pigmentary retinopathy, and multiple tubular stenoses (e.g., bile ducts, ureters). Other system involvement is variable. Rotation anomalies of the gut and cardiac abnormalities are frequently present. Pathogenesis remains obscure. Our patient was delivered at 33 weeks of gestation by cesarean section, and was jaundiced, with low birth weight and height. On day 5 after birth, the patient underwent Ladd's surgery for intestinal malrotation. One month later, she developed pyelonephritis and urosepsis. She remained jaundiced and a liver biopsy revealed cirrhosis with regenerating nodules, portal chronic inflammation with bile duct proliferation, and lobular cholestasis. The patient underwent several corrective operations, and at 12 months of age she was diagnosed with Hardikar syndrome. She failed to thrive and had progressive cholestasis and jaundice, coagulation disorders, bilateral ureterostomies, repetitive urinary tract infections, bilateral cleft lip and palate, retinopathy, and gut malrotation. She received a liver transplant at 24 months of age from a living donor. She has had an excellent clinical outcome in liver function without further decline of growth and development.
- Published
- 2002
- Full Text
- View/download PDF
42. Prospective validation of quantitative polymerase chain reaction for management of cytomegalovirus disease in solid-organ transplant patients.
- Author
-
Fisher RA, Saggi BH, Ferreira-Gonzalez A, Wolfe L, and Posner MP
- Subjects
- Adolescent, Adult, Cytomegalovirus Infections drug therapy, Ganciclovir therapeutic use, Humans, Middle Aged, Prospective Studies, Cytomegalovirus Infections diagnosis, Kidney Transplantation adverse effects, Liver Transplantation adverse effects, Polymerase Chain Reaction methods, Viral Load
- Abstract
This study evaluates the utility of quantitative polymerase chain reaction (QPCR) to determine duration of treatment of transplant patients with human cytomegalovirus (HCMV) disease. Eighteen patients with HCMV disease were prospectively evaluated and followed for recurrence using a QPCR assay. We used plasma samples from which nucleic acid was extracted. Quantification was determined by using an internal standard that contained the same primer sequences as for HCMV. During treatment, weekly QPCR assays were performed. Patients were treated with HCMV immunoglobulin-G for a finite period, but intravenous ganciclovir was continued until less than 100 viral copies (vc) per mL was detectable. After cessation of therapy, patients were followed for 6 months with monthly clinical assessment and QPCR. No patient developed recurrence of HCMV at a mean follow-up of 16 months. This preliminary study suggests that the use of QPCR to assess viral load is useful in deciding the length of HCMV treatment with ganciclovir but requires further randomized validation.
- Published
- 2002
- Full Text
- View/download PDF
43. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent.
- Author
-
Cotterell AH, Fisher RA, King AL, Gehr TW, Dawson S, Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Shiffman ML, and Posner MP
- Subjects
- Adult, Aged, Female, Humans, Kidney drug effects, Liver Transplantation adverse effects, Male, Middle Aged, Calcineurin Inhibitors, Immunosuppressive Agents therapeutic use, Liver Transplantation immunology, Sirolimus therapeutic use
- Abstract
The purpose of this study was to determine whether calcineurin inhibitor (CNI)-induced chronic nephrotoxicity in liver transplant patients is reversible by replacement of the CNI with rapamycin as the primary immunosuppressive agent. CNIs, while providing potent immunosuppression for liver transplant patients, exhibit nephrotoxicity as a major side-effect. Whereas acute CNI-induced nephrotoxicity is reversible by withdrawal of the CNI, chronic nephrotoxicity due to CNIs is a progressive process thought to be irreversible. Eight liver transplant patients with CNI-induced chronic nephrotoxicity were converted to rapamycin as the primary immunosuppressive agent. The CNI was either discontinued (four patients) or the dosage lowered to maintain a subtherapeutic level (four patients). Renal function as assessed by serum creatinine was measured before and after conversion to rapamycin. Two patients progressed to dialysis dependence following conversion to rapamycin. These two patients had been on CNIs for a mean of 112 months (range 93-131 months) prior to conversion to rapamycin. Five patients experienced improvement in renal function. These patients had been on calcineurin inhibitors for a mean of 60 months (range 42-75 months) prior to conversion. One patient with chronic nephrolithiasis as a contributing factor to his renal dysfunction has progressed to dialysis dependence despite conversion to rapamycin following exposure to a CNI for 24 months. In the five patients with improved renal function, serum creatinine levels decreased significantly (2.4 +/- 0.3 mg/dL to 1.5 +/- 0.1 mg/dL, p < 0.05) by a mean of 7.2 months (range 5-10 months) after conversion from CNI to rapamycin-based immunosuppression. Liver function remained stable after conversion to rapamycin. CNI-induced chronic nephrotoxicity can be reversed upon withdrawal of the CNI. Rapamycin is an effective replacement agent as primary immunosuppressive therapy following withdrawal of CNIs in liver transplant patients with CNI-induced chronic nephrotoxicity.
- Published
- 2002
- Full Text
- View/download PDF
44. Hepatocellular carcinoma: strategy for optimizing surgical resection, transplantation and palliation.
- Author
-
Fisher RA, Maroney TP, Fulcher AS, Maluf D, Clay JA, Wolfe LG, Dawson S 3rd, Cotterell A, Stravitz RT, Luketic VA, Shiffman M, Sterling RK, and Posner MP
- Subjects
- Adult, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular surgery, Combined Modality Therapy, Cryotherapy, Female, Humans, Infusions, Intra-Arterial, Liver Neoplasms pathology, Liver Neoplasms surgery, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Palliative Care, Prospective Studies, Carcinoma, Hepatocellular therapy, Chemoembolization, Therapeutic, Liver Neoplasms therapy, Liver Transplantation
- Abstract
In December 1997, a prospective study with informed consent was initiated to test a neoadjuvant treatment of transcatheter hepatic arterial chemo-embolization (TACE) and thermal or chemical ablation followed by transcatheter hepatic arterial chemo-infusion (TACI) in patients with hepatocellular carcinoma (HCC) referred for transplantation (OLT) and for resection. Patients were staged with American Liver Tumor Study Group-modified tumour-node-metastasis (TNM) staging classification using serial 3-6 month physical exam, alphafetoprotein (AFP), abdominal enhanced MRI, chest CT and bone scan. Sixty-five patients with HCC, out of 508 patients referred for OLT, were divided into five clinical groups and an incidental HCC patient group (n = 8), diagnosed on post-transplant explant pathology. The key focus of study was safety, site of HCC recurrence and tumour free survival. One hundred and thirty three ablation, infusion procedures were performed with an overall 24.8% morbidity, including two septic deaths. There were 13 (21.6%) HCC recurrences in 60 patients having one or more ablative treatments with only 23% hepatic HCC recurrences at 43 months of study. Eighteen HCC patients were listed for OLT (Group 3), with 12 patients transplanted after 29-424 d waiting. Two patients were removed from the OLT list due to HCC metastases, waiting a mean of 145 d. Two patients, post-OLT, had their TNM score upgraded from T2, T3 to T4. No Group 3 post-OLT patient has died or had HCC recurrence at mean follow-up of 27 +/- 15 months. No incidental HCC group post-OLT patient has died or had HCC recurrence at mean follow-up of 24 +/- 14 months. This neoadjuvant protocol is safe and effective in reducing HCC recurrence prior to and after OLT and resection.
- Published
- 2002
- Full Text
- View/download PDF
45. The interrelationship between portal and arterial blood flow after adult to adult living donor liver transplantation.
- Author
-
Marcos A, Olzinski AT, Ham JM, Fisher RA, and Posner MP
- Subjects
- Adult, Blood Flow Velocity, Body Weight, Cadaver, Hepatic Artery diagnostic imaging, Humans, Liver Transplantation diagnostic imaging, Liver Transplantation pathology, Living Donors, Portal Vein diagnostic imaging, Ultrasonography, Hepatic Artery physiology, Liver Circulation, Liver Transplantation physiology, Portal Vein physiology
- Abstract
Background: When adults are transplanted with segmental grafts, disparity between the size of the graft and the native organ is almost universal. These grafts presumably still receive all of the native portal inflow despite a reduced vascular bed and dramatically elevated blood flow may result. The hemodynamic changes after segmental transplantation in adults have not yet been studied and their clinical significance is unknown., Methods: Portal venous and hepatic arterial blood flow were measured intraoperatively in right lobe liver donors and recipients with electromagnetic flow probes. Postoperative evolution was monitored in recipients with ultrasonography., Results: Portal flow to the right lobe ranged from 601 to 1,102 ml/min before resection and from 1,257 to 2,362 ml/min after transplantation. There was a statistically significant linear correlation between the change in portal flow and graft to recipient body weight ratio. Arterial blood flow ranged from 213 to 460 ml/min before resection and from 60 to 300 ml/min after transplantation. Preoperative portal peak systolic velocity was uniformly around 10 cm/sec. Values on postoperative day 1 were increased to 30 cm/sec in recipients of cadaveric organs, to 50 cm/sec in recipients of organs with graft to recipient body weight ratios of more than 1.2%, and to 115 cm/sec in recipients of organs with ratios less than 0.9%. A decreasing tendency was universally observed. Arterial systolic velocity was inversely related to portal systolic velocity. Neither graft dysfunction nor vascular complications occurred., Conclusions: The hemodynamic pattern after right lobe transplantation is predictable and intraoperative measurements and ultrasonography are useful for monitoring. The size of the graft influences the magnitude of the hemodynamic changes.
- Published
- 2000
- Full Text
- View/download PDF
46. Selection and outcome of living donors for adult to adult right lobe transplantation.
- Author
-
Marcos A, Fisher RA, Ham JM, Olzinski AT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Olbrisch ME, and Posner MP
- Subjects
- Adult, Biopsy, Follow-Up Studies, Hepatectomy, Humans, Liver pathology, Postoperative Complications, Liver Transplantation, Living Donors, Personnel Selection methods, Tissue and Organ Procurement
- Abstract
Background: The shortage of cadaveric livers has sparked an interest in adult-to-adult living donor transplantation. Right lobe donor hepatectomy is frequently required to obtain a graft of adequate size for adult recipients. Careful donor selection is necessary to minimize complications and assure a functional graft., Methods: A four-step evaluation protocol was used for donor selection and satisfactory results of all tests in each step were required before proceeding to the next. Donors were selected based on a battery of laboratory studies chosen to exclude unrecognized infection, liver disease, metabolic disorders, and conditions representing undue surgical risk. Imaging studies included ultrasonography, angiography, magnetic resonance imaging, and intraoperative cholangiography and ultrasonography. The information obtained from liver biopsy was used to correct the estimated graft mass for the degree of steatosis., Results: From March 1998 to August 1999, 126 candidates were evaluated for living donation. A total of 35 underwent donor right lobectomy with no significant complications. Forty percent of all donors that came to surgery were genetically unrelated to the recipient. A total of 69% of those evaluated were excluded. ABO incompatibility was the primary reason for exclusion after the first step (71%) and the presence of steatosis yielding an inadequate estimated graft mass after the second step (20%)., Conclusions: Donor selection limits the application of living donor liver transplantation in the adult population. Unrelated individuals increase the size of the donor pool. Right lobe hepatectomy can be performed safely in healthy adult liver donors. Preoperative liver biopsy is an essential part of the evaluation protocol, particularly when the estimated graft mass is marginal.
- Published
- 2000
- Full Text
- View/download PDF
47. Surgical management of anatomical variations of the right lobe in living donor liver transplantation.
- Author
-
Marcos A, Ham JM, Fisher RA, Olzinski AT, and Posner MP
- Subjects
- Adult, Humans, Liver Diseases surgery, Middle Aged, Portal System anatomy & histology, Hepatectomy methods, Liver anatomy & histology, Liver Transplantation methods, Living Donors
- Abstract
Objective: To review the anatomical variations of the right lobe encountered in 40 living liver donors, describe the surgical management of these variations, and summarize the results of these procedures., Summary Background Data: Anatomical variability is the rule rather than the exception in liver and biliary surgery. To make effective use of liver segments from living donors for transplantation, surgical techniques must be adapted to the anomalies., Methods: Donor evaluation included celiac and mesenteric angiography with portal phase, magnetic resonance angiography, and intraoperative ultrasonography and cholangiography. Arterial anastomoses were generally between the donor right hepatic artery and the recipient main hepatic artery. Jump-grafts were constructed for recipients with hepatic artery thrombosis, and double donor arteries were joined to the bifurcation of the recipient hepatic artery. The branches of a trifurcated donor portal vein were isolated during the parenchymal transection, joined in a common cuff, and anastomosed to the recipient main portal vein. Significant accessory hepatic veins were preserved, brought together in a common cuff if multiple, and anastomosed to the recipient cava. The bile ducts were individually drained through a Roux-en-Y limb, and stents were placed in most patients., Results: Forty right lobe liver transplants were performed between adults. No donor was excluded because of prohibitive anatomy. Seven recipients had a prior transplant and five had a transjugular intrahepatic portosystemic shunt (TIPS). Arterial anomalies were noted in six donors and portal anomalies in four. Arterial jump-grafts were required in three. Sixteen had at least one significant accessory hepatic vein, and one had a double right hepatic vein. There were no vascular complications. Multiple bile ducts were found in 27 donors. Biliary complications occurred in 33% of patients without stents and 4% with stents., Conclusions: Anatomical variations of the right lobe can be accommodated without donor complications or complex reconstruction. Previous transplantation and TIPS do not significantly complicate right lobe transplantation. Microvascular arterial anastomosis is not necessary, and vascular complications should be infrequent. Biliary complications can be minimized with stenting.
- Published
- 2000
- Full Text
- View/download PDF
48. Emergency adult to adult living donor liver transplantation for fulminant hepatic failure.
- Author
-
Marcos A, Ham JM, Fisher RA, Olzinski AT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, and Posner MP
- Subjects
- Adult, Emergencies, Hepatectomy, Hepatic Encephalopathy virology, Hepatitis B complications, Humans, Liver anatomy & histology, Liver Function Tests, Magnetic Resonance Imaging, Male, Nuclear Family, Tissue and Organ Harvesting, Hepatic Encephalopathy surgery, Liver Transplantation methods, Living Donors
- Abstract
Background: The high mortality rate associated with fulminant hepatic failure combined with the limited availability of cadaveric organs requires consideration of alternatives to conventional cadaveric transplantation. Use of the donor right lobe in adult-to-adult living donor transplantation holds promise in a variety of circumstances, including high-acuity situations., Methods: A 28-year-old male with fulminant hepatic failure secondary to hepatitis B was referred to our institution. He rapidly progressed to grade IV encephalopathy, and laboratory values were indicative of a poor prognosis without transplantation. He was listed for transplantation as UNOS status I. Three siblings were simultaneously evaluated for living liver donation. Following established protocols, we completed donor evaluation in less than 24 hr, and donor right lobectomy and living donor transplantation were performed within 36 hr of the recipient's admission to our center., Results: The donor surgery was uncomplicated, and the patient was discharged on postoperative day 4. The recipient experienced full recovery and was discharged home on postoperative day 14. Of note, the first offer for a cadaveric liver came more than 60 hr after living donor transplantation., Conclusions: Thorough donor workup can be completed in less than 24 hr without inappropriate abbreviation of the evaluation. Simultaneous workup of willing individuals prevents unnecessary delay. Living donor transplantation should be considered for patients with fulminant hepatic failure who are appropriate transplant candidates.
- Published
- 2000
- Full Text
- View/download PDF
49. Emergency portacaval shunt for control of hemorrhage from a parenchymal fracture after adult-to-adult living donor liver transplantation.
- Author
-
Marcos A, Fisher RA, Ham JM, Olzinski AT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, and Posner MP
- Subjects
- Adult, Female, Humans, Iatrogenic Disease, Liver Regeneration, Living Donors, Magnetic Resonance Imaging, Male, Middle Aged, Reoperation, Emergencies, Hemorrhage, Liver Diseases, Liver Transplantation, Portacaval Shunt, Surgical, Postoperative Complications
- Abstract
As more adults undergo transplantation with partial liver grafts, the unique features of these segments and their clinical significance will become apparent. A patient presented with life-threatening hemorrhage from an iatrogenic laceration to a right lobe graft 11 days after transplantation. The creation of a portacaval shunt effectively controlled the bleeding, allowing more elective replacement of the organ with another right lobe graft. The regeneration process combined with increased portal blood flow and relative outflow limitation may have set the stage for this complication. Any disruption of the liver parenchyma during transplantation should be securely repaired and followed cautiously. Portacaval shunting is an option for controlling hemorrhage from the liver in transplant recipients. The timely availability of a second organ was likely the ultimate determinant of survival for this patient.
- Published
- 2000
- Full Text
- View/download PDF
50. Single-center analysis of the first 40 adult-to-adult living donor liver transplants using the right lobe.
- Author
-
Marcos A, Ham JM, Fisher RA, Olzinski AT, and Posner MP
- Subjects
- Adult, Humans, Immunosuppressive Agents therapeutic use, Liver Transplantation adverse effects, Middle Aged, Treatment Outcome, Liver Transplantation methods, Living Donors
- Abstract
The first adult-to-adult living donor liver transplant using the right hepatic lobe in the United States was performed only 2 years ago. Although initial reports were encouraging, continuous review of the results and appropriate modifications in patient management will be necessary to minimize donor risk and optimize recipient outcome. The results of 40 such transplantations were analyzed and are summarized. Recipients were listed for transplantation according to the usual criteria. Living donors were not considered for United Network for Organ Sharing status IIA patients after the initial 22 patients. Donor evaluation followed a rigid protocol. A graft-to-recipient body weight ratio of at least 0.8% was the minimum required throughout most of the study. The surgical procedures were similar, except the plane of transection was modified to better accommodate donor biliary anatomy, and uniform stenting of bile ducts was practiced after the first 10 transplants. Immunosuppression consisted of tacrolimus, mycophenolate mofetil, and a prednisone taper. The target tacrolimus level was decreased and mycophenolate was withdrawn more rapidly in the second half of the study because of the absence of acute cellular rejection. Donor morbidity has been limited to minor complications, and transplant recipient biliary complications decreased from 35% to 0%. Acute cellular rejection has not been observed despite less aggressive immunosuppression, and septic complications decreased dramatically. There have been no recipient deaths since these changes were instituted. Right lobectomy can be performed safely in the donor population. Recipient biliary complications can be minimized with stenting. Less aggressive immunosuppression is well tolerated and minimizes septic complications and attributable mortality.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.